Latvia - latvisk - Adama

adama - suspo-emulsija - florasulams + fluroksipirs - herbicīdi

Latvia - latvisk - Adama

adama - šķīstošas granulas - metil-tribenurons - herbicīdi

Latvia - latvisk - Zāļu valsts aģentūra

linde gas, sweden - skābeklis - medicīniskā gāze, kriogēna - 100%

Latvia - latvisk - Zāļu valsts aģentūra

linde gas, sweden - skābeklis - medicīniskā gāze, saspiesta - 100%

Latvia - latvisk - Pārtikas un veterinārais dienests, Zemkopības ministrija

ražots Šveicē pēc uab „acorus calamus” pasūtījuma - pastila

Latvia - latvisk - Pārtikas un veterinārais dienests, Zemkopības ministrija

ražots Šveicē pēc uab „acorus calamus” pasūtījuma - pastila

Den europeiske union - latvisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiple mieloma - antineoplastiski līdzekļi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den europeiske union - latvisk - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - limfoma, folikulāra - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Den europeiske union - latvisk - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den europeiske union - latvisk - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastiski līdzekļi - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.